[{"id":"4baf504a-3428-46d7-aa11-1c6d5b48f340","acronym":"ACTION-1","url":"https://clinicaltrials.gov/study/NCT05477576","created_at":"2022-07-28T14:55:31.876Z","updated_at":"2025-02-25T17:37:59.568Z","phase":"Phase 3","brief_title":"Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","source_id_and_acronym":"NCT05477576 - ACTION-1","lead_sponsor":"RayzeBio, Inc.","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • lanreotide prolonged-release subcutaneous • octreotide acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 288","initiation":"Initiation: 03/24/2022","start_date":" 03/24/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-01-29"},{"id":"77bffc42-2b22-4b22-8139-b83130b4cbfe","acronym":"COMPOSE","url":"https://clinicaltrials.gov/study/NCT04919226","created_at":"2021-06-10T01:52:29.850Z","updated_at":"2025-02-25T17:37:09.573Z","phase":"Phase 3","brief_title":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","source_id_and_acronym":"NCT04919226 - COMPOSE","lead_sponsor":"ITM Solucin GmbH","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • everolimus • temozolomide • capecitabine • oxaliplatin • leucovorin calcium • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2025-01-29"},{"id":"470be808-bc58-41ba-9198-bd615bd2748f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04711135","created_at":"2021-02-11T16:55:42.049Z","updated_at":"2024-07-02T16:34:25.979Z","phase":"Phase 2","brief_title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","source_id_and_acronym":"NCT04711135","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 03/12/2024","primary_completion_date":" 03/12/2024","study_txt":" Completion: 05/07/2029","study_completion_date":" 05/07/2029","last_update_posted":"2024-06-14"},{"id":"8958a804-5b40-4f07-97d2-e49b0ff21eec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04946305","created_at":"2021-06-30T17:54:27.285Z","updated_at":"2024-07-02T16:34:25.830Z","phase":"","brief_title":"A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea","source_id_and_acronym":"NCT04946305","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 05/10/2022","start_date":" 05/10/2022","primary_txt":" Primary completion: 07/08/2024","primary_completion_date":" 07/08/2024","study_txt":" Completion: 07/08/2024","study_completion_date":" 07/08/2024","last_update_posted":"2024-06-14"},{"id":"2d466bac-cc21-4880-9a02-9ce432c80a1e","acronym":"ETCTN 10388","url":"https://clinicaltrials.gov/study/NCT04234568","created_at":"2023-12-06T21:16:22.996Z","updated_at":"2024-07-02T16:34:26.307Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors","source_id_and_acronym":"NCT04234568 - ETCTN 10388","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Triapine (3-AP)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/20/2020","start_date":" 07/20/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-13"},{"id":"9236ed5b-4e48-4482-beb7-c4a2d4ec1f1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05844332","created_at":"2023-05-06T15:04:24.810Z","updated_at":"2024-07-02T16:34:27.152Z","phase":"","brief_title":"LUTATHERA Injection General Use Result Survey","source_id_and_acronym":"NCT05844332","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 347","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-11"},{"id":"3860705e-302a-47ca-86d2-2608fd1b0f73","acronym":"","url":"https://clinicaltrials.gov/study/NCT05247905","created_at":"2022-02-21T14:52:59.210Z","updated_at":"2024-07-02T16:35:01.279Z","phase":"Phase 2","brief_title":"Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors","source_id_and_acronym":"NCT05247905","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • capecitabine • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 03/16/2022","start_date":" 03/16/2022","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 10/01/2033","study_completion_date":" 10/01/2033","last_update_posted":"2024-05-23"},{"id":"076eece4-6905-454a-8a07-8b842556ea06","acronym":"","url":"https://clinicaltrials.gov/study/NCT05595460","created_at":"2022-10-27T15:58:19.568Z","updated_at":"2024-07-02T16:35:01.901Z","phase":"Phase 1","brief_title":"Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC","source_id_and_acronym":"NCT05595460","lead_sponsor":"RayzeBio, Inc.","biomarkers":" PD-L1 • SSTR","pipe":" | ","alterations":" SSTR positive","tags":["PD-L1 • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 10/10/2022","start_date":" 10/10/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-22"},{"id":"0a7abb08-ccb1-4e69-80bd-9e92b2a533e2","acronym":"NETTER-2","url":"https://clinicaltrials.gov/study/NCT03972488","created_at":"2021-02-11T16:53:55.907Z","updated_at":"2024-07-02T16:35:03.576Z","phase":"Phase 3","brief_title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","source_id_and_acronym":"NCT03972488 - NETTER-2","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • octreotide acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 226","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 07/20/2023","primary_completion_date":" 07/20/2023","study_txt":" Completion: 10/29/2027","study_completion_date":" 10/29/2027","last_update_posted":"2024-05-15"},{"id":"3dd674e6-b496-4d73-a6b8-026abbece6f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05142696","created_at":"2021-12-02T15:53:46.962Z","updated_at":"2024-07-02T16:35:06.048Z","phase":"Phase 1/2","brief_title":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","source_id_and_acronym":"NCT05142696","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • Tevimbra (tislelizumab-jsgr) • etoposide IV • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 05/05/2025","primary_completion_date":" 05/05/2025","study_txt":" Completion: 05/03/2028","study_completion_date":" 05/03/2028","last_update_posted":"2024-05-03"},{"id":"788d5186-c5e0-4cdd-ba52-51d8b5d8095b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04544098","created_at":"2021-02-11T16:55:22.383Z","updated_at":"2024-07-02T16:35:06.529Z","phase":"Phase 1","brief_title":"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","source_id_and_acronym":"NCT04544098","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-02"},{"id":"90bc3653-4e66-4df1-bfe9-4abee846b758","acronym":"iPRRT","url":"https://clinicaltrials.gov/study/NCT05583708","created_at":"2022-10-18T14:57:03.428Z","updated_at":"2024-07-02T16:35:09.073Z","phase":"Phase 2","brief_title":"Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer","source_id_and_acronym":"NCT05583708 - iPRRT","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/03/2023","start_date":" 08/03/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-04-17"},{"id":"0e0834be-0c1a-4cc9-89e5-a3e0950833c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04082520","created_at":"2021-02-11T16:54:03.522Z","updated_at":"2024-07-02T16:35:12.274Z","phase":"Phase 2","brief_title":"Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","source_id_and_acronym":"NCT04082520","lead_sponsor":"Mayo Clinic","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 09/04/2024","primary_completion_date":" 09/04/2024","study_txt":" Completion: 09/04/2025","study_completion_date":" 09/04/2025","last_update_posted":"2024-03-29"},{"id":"fa4ac16f-1835-4662-8af1-7fcab76575bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06016855","created_at":"2023-08-30T14:08:43.881Z","updated_at":"2024-07-02T16:35:12.390Z","phase":"Phase 4","brief_title":"Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors","source_id_and_acronym":"NCT06016855","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 04/30/2024","start_date":" 04/30/2024","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2024-03-28"},{"id":"27145ff7-4899-4e16-a0c3-153894083c4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05475210","created_at":"2022-07-26T17:10:16.861Z","updated_at":"2024-07-02T16:35:15.078Z","phase":"Phase 1","brief_title":"177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors","source_id_and_acronym":"NCT05475210","lead_sponsor":"Molecular Targeting Technologies, Inc.","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 177Lu-EBTATE"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 06/18/2022","start_date":" 06/18/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2024-03-13"},{"id":"35e34361-ae0b-4c69-8d47-4171b1f9736a","acronym":"PROMENADE","url":"https://clinicaltrials.gov/study/NCT04997317","created_at":"2021-08-09T13:53:17.457Z","updated_at":"2024-07-02T16:35:15.190Z","phase":"Phase 1","brief_title":"Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide","source_id_and_acronym":"NCT04997317 - PROMENADE","lead_sponsor":"University Hospital, Basel, Switzerland","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SOMther (lutetium-177 DOTA satoreotide) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/21/2021","start_date":" 04/21/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-12"},{"id":"45acda49-4eea-4ad8-bb32-a2e6799876f3","acronym":"START-NET","url":"https://clinicaltrials.gov/study/NCT05387603","created_at":"2022-05-24T12:54:25.088Z","updated_at":"2024-07-02T16:35:15.531Z","phase":"Phase 3","brief_title":"Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.","source_id_and_acronym":"NCT05387603 - START-NET","lead_sponsor":"Lund University Hospital","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-03-08"},{"id":"abe95a5f-8246-429d-92a8-a73471011fbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01876771","created_at":"2021-01-18T08:24:57.554Z","updated_at":"2024-07-02T16:35:21.860Z","phase":"Phase 2","brief_title":"A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours","source_id_and_acronym":"NCT01876771","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 04/29/2014","start_date":" 04/29/2014","primary_txt":" Primary completion: 12/01/2033","primary_completion_date":" 12/01/2033","study_txt":" Completion: 12/01/2033","study_completion_date":" 12/01/2033","last_update_posted":"2024-01-30"},{"id":"a595dd39-de19-445b-833b-30837dcc200d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05610826","created_at":"2022-11-09T13:56:42.488Z","updated_at":"2024-07-02T16:35:21.904Z","phase":"Phase 1/2","brief_title":"Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver","source_id_and_acronym":"NCT05610826","lead_sponsor":"University of Chicago","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-01-29"},{"id":"2ce71cc8-c99e-442e-ada8-43ed288e9bdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06121271","created_at":"2023-11-07T16:14:39.298Z","updated_at":"2024-07-02T16:35:26.861Z","phase":"Phase 2","brief_title":"Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications","source_id_and_acronym":"NCT06121271","lead_sponsor":"University College, London","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 11/06/2027","primary_completion_date":" 11/06/2027","study_txt":" Completion: 11/06/2027","study_completion_date":" 11/06/2027","last_update_posted":"2023-12-07"},{"id":"01ee014a-7d08-4da3-a0a3-f28ad90c284a","acronym":"COMPETE","url":"https://clinicaltrials.gov/study/NCT03049189","created_at":"2021-01-18T15:00:56.649Z","updated_at":"2024-07-02T16:35:27.442Z","phase":"Phase 3","brief_title":"Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients","source_id_and_acronym":"NCT03049189 - COMPETE","lead_sponsor":"ITM Solucin GmbH","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 309","initiation":"Initiation: 02/02/2017","start_date":" 02/02/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2023-11-30"},{"id":"3570464a-977a-4c4b-b9ce-da03668a6a6f","acronym":"LEVEL","url":"https://clinicaltrials.gov/study/NCT05918302","created_at":"2023-06-26T14:09:09.001Z","updated_at":"2024-07-02T16:35:30.525Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","source_id_and_acronym":"NCT05918302 - LEVEL","lead_sponsor":"Grupo Espanol de Tumores Neuroendocrinos","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 10/27/2023","start_date":" 10/27/2023","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2023-11-02"},{"id":"4401c394-5d2d-4472-8e80-7bc5059b71df","acronym":"LUFOR","url":"https://clinicaltrials.gov/study/NCT06045260","created_at":"2023-09-21T15:10:50.581Z","updated_at":"2024-07-02T16:35:36.405Z","phase":"Phase 2","brief_title":"\"Receptor Radionuclide Therapy With 177Lu-DOTATOC","source_id_and_acronym":"NCT06045260 - LUFOR","lead_sponsor":"Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 positive","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Solucin (177Lu-edotreotide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-09-21"},{"id":"0d0d15de-eb4a-4e35-9e1e-388c588b5f9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03971461","created_at":"2021-01-18T19:32:12.909Z","updated_at":"2024-07-02T16:35:40.851Z","phase":"Phase 2","brief_title":"Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma","source_id_and_acronym":"NCT03971461","lead_sponsor":"NYU Langone Health","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR2 positive","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/15/2019","start_date":" 05/15/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-08-04"}]